Systemic mycotic infections due to susceptible organisms. Fever of unknown origin in neutropenic patients. As primary therapy of visceral leishmaniasis in immunocompetent adult & childn patients & in immunocompromised patients.
Dosage must be adjusted to the specific requirements of each patient. Recommended IV infusion: 0.2-2 mg/mL. Adult Systemic mycotic infections Daily dose of 1 mg/kg; increase stepwise to 3 mg/kg as required. Fever of unknown origin Initiate at 1 mg/kg/day; raise to 3 mg/kg/day if indicated. Visceral leishmaniasis 1-1.5 mg/kg/day for 21 days or alternatively 3 mg/kg/day for 10 days. Paed patient 1 mth-18 yr Calculate dosage on the same per kg body wt basis as for adults.
Anaphylaxis & anaphylactoid reactions; other severe infusion-related reactions; acute pulmonary toxicity during or shortly after leukocyte transfusions; renal adverse reactions. Perform regular laboratory evaluation of serum electrolytes (particularly K & Mg), renal, hepatic & haematopoietic function. Contains approx 900 mg sucrose in each vial; caution in DM patients. Avoid administration during haemodialysis or filtration procedures. Patients w/ rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Some adverse reactions may impair ability to drive or operate machinery. Pregnancy & lactation. Infant <1 mth.
Sign Out
